News and Events

It was October 2015 when the US immunotherapy market was celebrating its first-ever FDA-approved oncolytic virus therapy, talimogene laherparepve (T-VEC). Developed by Amgen, this new genre of immunotherapy demonstrated immense efficacy in treating advanced melanoma.

Check out the latest BioPharma Newsletter from the Eurofins Group to learn about new services and analytical techniques, research projects, major events and other related topics.

May 12-16

Learn something new at Bio-Rad's Exhibitor Showcase featuring Dr. Mark Wissel, Director of R & D at Viracor Eurofins BioPharma Services. Mark will be speaking about Implementing Droplet Digital PCR in a Clinical Trial Testing on May 12, 2021 at 11:35 AM EST.

Check out the latest Eurofins Viracor BioPharma Press Releases:

Check out the latest BioPharma Newsletter from the Eurofins Group to learn about new services and analytical techniques, research projects, major events and other related topics.

Dec 1-3

RT-qPCR and Sequencing Testing Supporting SARS-CoV-2 Vaccine Clinical Trials

Presented By Mark Wissel

Nov 19

Eurofins Viracor invites you to add the upcoming event to your calendar. This informative webinar; featuring Karina Eterovic, PhD, R&D Director of Oncology Diagnostics at Eurofins Viracor, entitled: Exploring the application of comprehensive genomic profiling in oncology therapy development.

Sept 28 - Oct 1

qPCR/sequencing assay development to support vaccine clinical studies and trials

Presented by Mark Wissel

Jul 29

Eurofins Viracor invites you to add the upcoming event to your calendar. This informative webinar, featuring our flow cytometry expert, Dr. Brian Maybruck, will focus on the use of Flow Cytometry for rare cell quantitation, and its application in drug development.

Flow cytometry is a very powerful and reliable alternative to many other methods used for clinical drug development. Consider that it can simultaneously measure multiple parameters on tens of thousands of cells, with a resolution down to a single cell level, robustly and rapidly (greater than 1000 samples per day).